

Prevention NOW!

May 2020 - Issue 57

CAB-LA Proves to Be Highly Effective for Prevention of HIV Acquisition in Cisgender Men and Transgender Women



HPTN researchers announced on Monday, May 18, results from <u>HPTN 083</u>, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men.

Read More

Infectious Diseases Have Rules: Lessons From the Past for Facing COVID-19



As the COVID-19 pandemic impacts the U.S. healthcare system, it's also raising our anxiety levels to a fevered pitch. In this opinion editorial, HPTN co-PIs Dr. Myron Cohen and Dr. Wafaa EI-Sadr offer readers some hope and reassurance. Drawing on their experience in confronting HIV, SARS, and other pandemics, they remind us we have been here before, facing and controlling emergent viruses. By following basic steps to learn COVID-19's pathogenesis — its development, who it attacks, and why — we can win this battle, too.

Read More

Combination Prevention for COVID-19



HPTN co-PI Dr. Myron Cohen and HIV Vaccine Trials Network PI Dr. Lawrence Corey discuss COVID-19 prevention strategies, based on years of fighting HIV, in this *Science* magazine editorial.

Read More

Shoutout



Congratulations to HPTN co-PI Dr. Myron Cohen for being inducted into The University of North Carolina at Chapel Hill Order of the Golden Fleece, the school's oldest and most prestigious honor society. The Order selects members based upon service to the university as reflected in scholarship, motivation, creativity, loyalty, and leadership in academic and extracurricular pursuits.

Network Member Spotlight


Pumeza Mzizi, a member of the <u>HPTN 084</u> Community Working Group, is a community liaison officer for the Ward 21 clinical research site (CRS) at Wits RHI in Johannesburg. She has coordinated community engagement in randomized clinical trials (RCTs) for the past 20 years. Pumeza was first introduced to RCTs in 2001 when working on the DART study that was enrolling pregnant women living with HIV to evaluate the single-dose nevirapine in preventing mother-to-child transmission. This project helped shape national policies and guidelines on the prevention of mother to child transmission. She has also been active in HIV prevention research for adolescent girls and young women, adult women, commercial sex workers and men.



Read More

Awareness Days





Margolis D, McCauley M, Hendrix CW, Landovitz RJ. <u>Hormonal Contraception Use and Cabotegravir</u> <u>Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.</u> J Acquir Immune Defic Syndr. 2020 May 21.

Okafor CN, Hucks-Ortiz C, Hightow-Weidman LB, Magnus M, Emel L, Beauchamp G, Kuo I, Hendrix C, Mayer KH, Shoptaw S. <u>Associations between Self-Reported Substance Use Behaviors and PrEP</u> Acceptance and Adherence among Black MSM in the HPTN 073 Study. J Acquir Immune Defic Syndr. 2020 May 21.

Elmes J, Silhol R, Hess KL, Gedge LM, Nordsletten A, Staunton R, Anton P, Shacklett B, McGowan I, Dang Q, Adimora AA, Dimitrov DT, Aral S, Handanagic S, Paz-Bailey G, Boily MC; NHBS Study Group. <u>Receptive anal sex contributes substantially to heterosexually-acquired HIV infections among at-risk</u> <u>women in Twenty US Cities: results from a modeling analysis.</u> Am J Reprod Immunol. 2020 May 8.

Brown BJ, Sugarman J. <u>Why ethics guidance needs to be updated for contemporary HIV prevention</u> research. J Int AIDS Soc. 2020 May;23(5):e25500.



What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at news@hptn.org.

Copyright © 2020 The HIV Prevention Trials Network, All rights reserved.